Nature1 个月
Canakinumab for the cryopyrin-associated periodic syndromes
Cryopyrin-associated periodic syndromes (CAPS) are a family of related conditions associated with heterozygous mutations in NLRP3 (formerly CIAS1), the gene that encodes the NACHT, LRR and PYD ...
华东医药「利纳西普」获批上市，自免领域再添新品
Insight 数据库显示，利纳西普早在 2008 年就获得美国 FDA 批准上市，商品名为 ARCALYST®，用于治疗 冷吡啉相关的周期性综合征 （CAPS），包括家族性寒冷型自身炎症综合征 （FCAS）和穆-韦二氏综合征 （MWS）；2020 ...
Nature5 年
IL-1 trap go-ahead
On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...
pharmaphorum8 年
FDA Breakthrough status for Novartis drug in Periodic Fever Syndromes
Ilaris was approved by the FDA in 2009 to treat two subtypes of a rare autoinflammatory disease called Cryopyrin-Associated Periodic Syndromes (CAPS): Muckle-Wells syndrome (MWS) and Familial Cold ...